Blog

Words Matter: a researcher’s obligation to think before speaking.

By Carly Young | October 12, 2022

As a teenager, I always said that I would dedicate my life to something meaningful. No matter how big or small the contribution, I vowed to commit my time and energy toward the betterment of others’ wellbeing. I was unsure of the exact route I would take but I trusted myself to know that I’d…

Read More...

Looking at the Future of TB Research as an Early Career Researcher

By Ryan M. Kane, MD, MPH and Hunter Spencer, DO | April 18, 2022

Despite the discovery of the causative agent of tuberculosis (TB) (Mycobacterium tuberculosis) by Robert Koch in 1882, there are still many questions regarding the pathophysiology of TB that remain unanswered—particularly in the differentiation and marked variability between latent (asymptomatic, non-transmissible) and active (symptomatic, transmissible) stages of infection. In 2020 the World Health Organization (WHO) estimated…

Read More...

TB advocates call on Europe to fulfil commitments for new TB vaccines

By Shaun Palmer | February 17, 2022

As representatives of communities affected by tuberculosis (TB) – including survivors, researchers and civil society organizations – we demand long overdue global investments in the research and development of new TB vaccines commensurate with the disease’s devastating impact. The sixth Global Forum on TB Vaccines will be virtually hosted by Toulouse, France this February 22–25…

Read More...

Leveraging COVID-19 public-private partnerships for TB vaccine development

By Ryan M. Kane, MD, MPH and Hunter Spencer, DO | February 8, 2022

The past few years have created a paradigm shift in the way we globally respond to and address communicable diseases. Though we remain in the midst of the COVID-19 pandemic, several novel vaccine candidates have been developed, manufactured, studied, approved, distributed, and administered to millions of individuals around the world in less than one year.…

Read More...

M72/ AS01E Works: Now What?

By Hunter Spencer, DO | May 25, 2021

We recently discussed M72/AS01E and the exciting data suggesting its efficacy in preventing progression of TB disease after people had already been exposed to TB. Today, we will put these findings into context. Some of the excitement regarding this trial stems from the novelty of its findings. Dr. Ann Ginsberg is a TB researcher working…

Read More...

Landmark Trial for Vaccine M72/AS01E

By Hunter Spencer, DO | August 9, 2020

Today, we will look at a landmark trial reporting the full results of a vaccine called M72/AS01E. This trial sought to answer the question: Can this vaccine decrease the rate of TB disease in adults who have already been exposed to TB1? Pulmonary TB, affects the lungs and is the most common form of the…

Read More...

Guest posts published on this blog reflect the views of their authors and persons interviewed and do not necessarily reflect the views of the Stop TB Partnership Working Group on New TB Vaccines.